Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company that develops precision genetic medicines for patients with serious diseases in the United States. Its programs focus on hematology and genetic diseases, including Ristoglogene autogetemcel, a patient-specific autologous hematopoietic stem cell (HSC) therapy for sickle cell disease. The company also has liver-targeting lipid nanoparticle (LNP) programs: BEAM-302 for severe alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. Additionally, Beam is developing the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs, and BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company collaborates with Pfizer Inc. on in vivo base editing programs for rare genetic diseases of the liver, muscle, and central nervous system, and has partnerships with Verve Therapeutics for cardiovascular treatments and Orbital Therapeutics for RNA-based therapies.

Beam Therapeutics Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BEAM. The company's stock is traded in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and share pricing are denominated in USD, making it accessible to investors on major US exchanges.

Beam Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. This classification reflects the company's focus on developing precision genetic medicines using advanced technologies like base editing. Biotechnology companies like Beam engage in research and development of therapeutic products derived from biological processes, often targeting rare or serious diseases. The industry is characterized by high R&D investment, regulatory milestones, and potential for breakthrough treatments.

Beam Therapeutics Inc. is headquartered in Cambridge, Massachusetts, United States. The company primarily serves the US market, as indicated by its focus on developing treatments for serious diseases in the United States. While its collaborations with Pfizer and other partners may have global implications, the company's operations and clinical programs are centered in the US. Cambridge is a major biotech hub, providing access to talent, research institutions, and funding.

Beam Therapeutics has a diverse portfolio of precision genetic medicines. Key product candidates include Ristoglogene autogetemcel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. The company also develops the ESCAPE platform and BEAM-103 antibody. Notable partnerships include a research collaboration with Pfizer Inc. focusing on in vivo base editing for rare genetic diseases of the liver, muscle, and central nervous system. Additionally, Beam has collaborations with Verve Therapeutics for cardiovascular disease treatments and Orbital Therapeutics to design RNA for prevention, treatment, or diagnosis of human disease.